Literature DB >> 10739512

Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?

D M Stamilio1, H M Sehdev, M A Morgan, K Propert, G A Macones.   

Abstract

OBJECTIVE: This study was undertaken to develop a multivariable clinical predictive rule for severe preeclampsia using second-trimester clinical factors and biochemical markers. STUDY
DESIGN: We performed a retrospective cohort study of all pregnant patients with single gestations from 1995 through 1997 for whom we had complete follow-up data. Through medical record review we determined whether patients had severe preeclampsia develop according to American College of Obstetricians and Gynecologists criteria. Case patients with severe preeclampsia were compared with control subjects with respect to clinical data and multiple-marker screening test results. With potential predictive factors identified in the bivariate and stratified analyses both an explanatory logistic regression model and a clinical prediction rule were created. Patients were assigned a predictive score according to the presence or absence of predictive factors, and receiver operating characteristic analysis was used to determine the optimal score cutoff point for prediction of severe preeclampsia with maximal sensitivity.
RESULTS: Among the 1998 patients we found 49 patients with severe preeclampsia (prevalence, 2.5%). After we controlled for confounding variables, case patients and control subjects had similar human chorionic gonadotropin and alpha-fetoprotein levels, and the only variables that remained significantly associated with severe preeclampsia were nulliparity (relative risk, 3.8; 95% confidence interval, 1.7-8.3), history of preeclampsia (relative risk, 5.0; 95% confidence interval, 1.7-17.2), elevated screening mean arterial pressure (relative risk, 3.5; 95% confidence interval, 1.7-7.2), and low unconjugated estriol concentration (relative risk, 1.7; 95% confidence interval, 0.9-3.4). Our predictive model for severe preeclampsia, which included only these 4 variables, had a sensitivity of 76% and a specificity of 46%.
CONCLUSION: Even after incorporation of the strongest risk factors, our predictive model had only modest sensitivity and specificity for discrimination of patients at risk for development of severe preeclampsia. The addition of the human chorionic gonadotropin and alpha-fetoprotein biochemical markers did not enhance the model's predictive value for severe preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739512     DOI: 10.1067/mob.2000.103890

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  21 in total

Review 1.  Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies.

Authors:  Kirsten Duckitt; Deborah Harrington
Journal:  BMJ       Date:  2005-03-02

2.  The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community.

Authors:  Fiona Milne; Chris Redman; James Walker; Philip Baker; Julian Bradley; Carol Cooper; Michael de Swiet; Gillian Fletcher; Mervi Jokinen; Deirdre Murphy; Catherine Nelson-Piercy; Vicky Osgood; Stephen Robson; Andrew Shennan; Angela Tuffnell; Sara Twaddle; Jason Waugh
Journal:  BMJ       Date:  2005-03-12

3.  Measuring antenatal care use in Europe: is the content and timing of care in pregnancy tool applicable?

Authors:  Katrien Beeckman; Lucy Frith; Helga Gottfreðsdóttir; Annette Bernloehr
Journal:  Int J Public Health       Date:  2017-03-09       Impact factor: 3.380

4.  Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.

Authors:  Jimmy Espinoza; Roberto Romero; Jyh Kae Nien; Ricardo Gomez; Juan Pedro Kusanovic; Luis F Gonçalves; Luis Medina; Sam Edwin; Sonia Hassan; Mario Carstens; Rogelio Gonzalez
Journal:  Am J Obstet Gynecol       Date:  2007-04       Impact factor: 8.661

Review 5.  Angiogenic factors in preeclampsia: potential for diagnosis and treatment.

Authors:  Arvind Goel; Sarosh Rana
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-11       Impact factor: 2.894

Review 6.  Pregnancy characteristics and maternal breast cancer risk: a review of the epidemiologic literature.

Authors:  Sarah Nechuta; Nigel Paneth; Ellen M Velie
Journal:  Cancer Causes Control       Date:  2010-03-12       Impact factor: 2.506

7.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

8.  Aberrant synthesis, metabolism, and plasma accumulation of circulating estrogens and estrogen metabolites in preeclampsia implications for vascular dysfunction.

Authors:  Sheikh O Jobe; Chanel T Tyler; Ronald R Magness
Journal:  Hypertension       Date:  2013-01-14       Impact factor: 10.190

Review 9.  Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis.

Authors:  Rachel K Morris; Jeltsje S Cnossen; Marloes Langejans; Stephen C Robson; Jos Kleijnen; Gerben Ter Riet; Ben W Mol; Joris A M van der Post; Khalid S Khan
Journal:  BMC Pregnancy Childbirth       Date:  2008-08-04       Impact factor: 3.007

10.  Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.

Authors:  Sarosh Rana; Camille E Powe; Saira Salahuddin; Stefan Verlohren; Frank H Perschel; Richard J Levine; Kee-Hak Lim; Julia B Wenger; Ravi Thadhani; S Ananth Karumanchi
Journal:  Circulation       Date:  2012-01-18       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.